Abstract

Virus-like particles (VLPs) are excellent tools for vaccines against pathogens and tumors. They can accommodate foreign polypeptides whose incorporation efficiency and immunogenicity however decrease strongly with the increase of their size. We recently described the CD8 + T cell immune response against a small foreign antigen (i.e., the 98 amino acid long human papilloma virus E7 protein) incorporated in human immunodeficiency virus (HIV)-1 based VLPs as product of fusion with an HIV-1 Nef mutant (Nef mut). Here, we extended our previous investigations by testing the antigenic/immunogenic properties of Nef mut-based VLPs incorporating much larger heterologous products, i.e., human hepatitis C virus (HCV) NS3 and influenza virus NP proteins, which are composed of 630 and 498 amino acids, respectively. We observed a remarkable cross-presentation of HCV NS3 in dendritic cells challenged with Nef mut–NS3 VLPs, as detected using a NS3 specific CD8 + T cell clone as well as PBMCs from HCV infected patients. On the other hand, when injected in mice, Nef mut–NP VLPs elicited strong anti-NP CD8 + T cell and CTL immune responses. In addition, we revealed the ability of Nef mut incorporated in VLPs to activate and mature primary human immature dendritic cells (iDCs). This phenomenon correlated with the activation of Src tyrosine kinase-related intracellular signaling, and can be transmitted from VLP-challenged to bystander iDCs. Overall, these results prove that Nef mut-based VLPs represent a rather flexible platform for the design of innovative CD8 + T cell vaccines.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call